Historical Valuation
Madrigal Pharmaceuticals Inc (MDGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.90 is considered Undervalued compared with the five-year average of 16.36. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 758.67 to 981.12 according to relative valuation methord. Compared to the current price of 514.06 USD , Madrigal Pharmaceuticals Inc is Undervalued By 32.24%.
Relative Value
Fair Zone
758.67-981.12
Current Price：514.06
32.24%
Undervalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Madrigal Pharmaceuticals Inc (MDGL) has a current Price-to-Book (P/B) ratio of 21.55. Compared to its 3-year average P/B ratio of 26.78 , the current P/B ratio is approximately -19.53% higher. Relative to its 5-year average P/B ratio of 26.89, the current P/B ratio is about -19.86% higher. Madrigal Pharmaceuticals Inc (MDGL) has a Forward Free Cash Flow (FCF) yield of approximately -1.20%. Compared to its 3-year average FCF yield of -6.27%, the current FCF yield is approximately -80.89% lower. Relative to its 5-year average FCF yield of -9.13% , the current FCF yield is about -86.88% lower.
P/B
Median3y
26.78
Median5y
26.89
FCF Yield
Median3y
-6.27
Median5y
-9.13
Competitors Valuation Multiple
AI Analysis for MDGL
The average P/S ratio for MDGL competitors is 39.49, providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL.O) exhibits a P/S ratio of 9.90, which is -74.93% above the industry average. Given its robust revenue growth of 362.03%, this premium appears sustainable.
Performance Decomposition
AI Analysis for MDGL
1Y
3Y
5Y
Market capitalization of MDGL increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of MDGL in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is MDGL currently overvalued or undervalued?
Madrigal Pharmaceuticals Inc (MDGL) is now in the Undervalued zone, suggesting that its current forward PS ratio of 9.90 is considered Undervalued compared with the five-year average of 16.36. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 758.67 to 981.12 according to relative valuation methord. Compared to the current price of 514.06 USD , Madrigal Pharmaceuticals Inc is Undervalued By 32.24% .
What is Madrigal Pharmaceuticals Inc (MDGL) fair value?
MDGL's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Madrigal Pharmaceuticals Inc (MDGL) is between 758.67 to 981.12 according to relative valuation methord.
How does MDGL's valuation metrics compare to the industry average?
The average P/S ratio for MDGL's competitors is 39.49, providing a benchmark for relative valuation. Madrigal Pharmaceuticals Inc Corp (MDGL) exhibits a P/S ratio of 9.90, which is -74.93% above the industry average. Given its robust revenue growth of 362.03%, this premium appears sustainable.
What is the current P/B ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Jan 11 2026?
As of Jan 11 2026, Madrigal Pharmaceuticals Inc (MDGL) has a P/B ratio of 21.55. This indicates that the market values MDGL at 21.55 times its book value.
What is the current FCF Yield for Madrigal Pharmaceuticals Inc (MDGL) as of Jan 11 2026?
As of Jan 11 2026, Madrigal Pharmaceuticals Inc (MDGL) has a FCF Yield of -1.20%. This means that for every dollar of Madrigal Pharmaceuticals Inc’s market capitalization, the company generates -1.20 cents in free cash flow.
What is the current Forward P/E ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Jan 11 2026?
As of Jan 11 2026, Madrigal Pharmaceuticals Inc (MDGL) has a Forward P/E ratio of 726.27. This means the market is willing to pay $726.27 for every dollar of Madrigal Pharmaceuticals Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Madrigal Pharmaceuticals Inc (MDGL) as of Jan 11 2026?
As of Jan 11 2026, Madrigal Pharmaceuticals Inc (MDGL) has a Forward P/S ratio of 9.90. This means the market is valuing MDGL at $9.90 for every dollar of expected revenue over the next 12 months.